Synuclein-γ (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma

Gynecologic Oncology

Volumn 114, Issue 2, 2009, Pages 293-298

  Morgan, Jacqueline ^a   Hoekstra, Anna V ^a   Chapman Davis, Eloise ^a   Hardt, Jennifer L ^a   Kim, J Julie ^a   Buttin, Barbara M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biomarker; Drug resistance; Prognosis; Serous carcinoma; Synuclein ; Uterine

Indexed keywords

BROXURIDINE; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLIGONUCLEOTIDE; PACLITAXEL; SYNUCLEIN; SYNUCLEIN GAMMA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER RESISTANCE; CELL ASSAY; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENDOMETRIUM CELL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERUS CARCINOMA; UTERUS TUMOR; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, PAPILLARY; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; GAMMA-SYNUCLEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; PACLITAXEL; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 67549114830     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.04.036     Document Type: Article

References (19)

1. Hendrickson M., Ross J., Eifel P., Martinez A., and Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Pathol. 6 (1982) 93-108
2. Hamilton C.A., Cheung M.K., Osann K., et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br. J. Cancer 94 (2006) 642-646
3. Goff B.A., Kato D., Schmidt R.A., et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol. Oncol. 54 (1994) 264-268
4. Nicklin J.L., and Copeland L.J. Endometrial papillary serous carcinoma: patterns of spread and treatment. Clin. Obstet. Gynecol. 39 (1996) 686-695
5. Hoskins P.J., Swenerton K.D., Pike J.A., et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J. Clin. Oncol. 19 (2001) 4048-4053
6. Ramondetta L., Burke T.W., Levenback C., Bevers M., Bodurka-Bevers D., and Gershenson D.M. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol. Oncol. 82 (2001) 156-161
7. Zanotti K.M., Belinson J.L., Kennedy A.W., Webster K.D., and Markman M. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol. Oncol. 74 (1999) 272-277
8. Vaidya A.P., Litell R., Krasner C., and Duska L.R. Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int. J. Gynecol. Cancer 16 (2006) 267-272
9. Lu A., Zhang F., Gupta A., and Liu J. Blockade of AP1 transactivation abrogates the abnormal expression of breast cancer specific gene 1 in breast cancer cells. J. Biol. Chem. 277 (2002) 31364-31372
10. Zhou Y., Inaba S., and Liu J. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment. Int. J. Oncol. 29 (2006) 289-295
11. Singh V.K., Zhou Y., March J.A., et al. Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs. Cancer Res. 67 (2007) 626-633
12. Kelly M.G., O'Malley D.M., Hui R., et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol. Oncol. 98 (2005) 353-359
13. Bruening W., Giasson B.I., Klein-Szanto A.J., Lee V.M., Trojanowski J.Q., and Godwin A.K. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 88 (2000) 2154-2163
14. Liu H., Liu W., Wu Y., et al. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res. 65 (2005) 7635-7643
15. Li Z., Sclabas G.M., Peng B., et al. Overexpression of synuclein-gamma in pancreatic adenocarcinoma. Cancer 101 (2004) 58-65
16. Jia T., Liu Y.E., Liu J., and Shi Y.E. Stimulation of breast cancer invasion and metastasis by synuclein gamma. Cancer Res. 59 (1999) 742-747
17. Lanni J.S., Lowe S.W., Licitra E.J., Liu J.O., and Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 9679-9683
18. Pan Z.Z., Bruening W., Glasson B.I., Lee V.M., and Godwin A.K. Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J. Biol. Chem. 277 (2002) 3505-3560
19. Gupta A., Inaba S., Wong O.K., Fang G., and Liu J. Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1. Oncogene 22 48 (2003) 7593-7599